Ghost Tree Capital, LLC Ascendis Pharma A/S Transaction History

Ghost Tree Capital, LLC

$267 Million
Q3 2024

A detailed history of Ghost Tree Capital, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Ghost Tree Capital, LLC holds 52,500 shares of ASND stock, worth $7.16 Million. This represents 2.94% of its overall portfolio holdings.

Number of Shares

52,500

Previous 86,721 39.46%

Holding current value

$7.16 Million

Previous $11.8 Million 33.71%

% of portfolio

2.94%

Previous 4.83%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $3.87 Million - $5.25 Million	-34,221 Reduced 39.46%	52,500 $7.84 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $10.5 Million - $13.3 Million	86,721 New	86,721 $11.8 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $5.6 Million - $8.28 Million	-65,000 Reduced 76.47%	20,000 $2.52 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $1.3 Million - $1.56 Million	-15,000 Reduced 15.0%	85,000 $7.96 Million
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $699,599 - $978,400	-10,000 Reduced 9.09%	100,000 $8.93 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $2.1 Million - $2.54 Million	-20,000 Reduced 15.38%	110,000 $11.8 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $3.48 Million - $4.62 Million	35,000 Added 36.84%	130,000 $15.9 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $1.68 Million - $2.2 Million	20,000 Added 26.67%	95,000 $9.81 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $5.08 Million - $7.64 Million	-65,000 Reduced 46.43%	75,000 $6.97 Million
Q1 2022 May 16, 2022	SELL	$102.18 - $135.75 $5.11 Million - $6.79 Million	-50,000 Reduced 26.32%	140,000 $16.4 Million
Q4 2021 Feb 16, 2022	BUY	$127.1 - $169.66 $8.9 Million - $11.9 Million	70,000 Added 58.33%	190,000 $25.6 Million
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $1.69 Million - $2.65 Million	-15,000 Reduced 11.11%	120,000 $19.1 Million
Q1 2021 May 14, 2021	BUY	$124.92 - $173.33 $3.75 Million - $5.2 Million	30,000 Added 28.57%	135,000 $17.4 Million
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $3.78 Million - $4.57 Million	-25,000 Reduced 19.23%	105,000 $17.5 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $8.73 Million - $10 Million	65,000 Added 100.0%	130,000 $20.1 Million
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $9.42 Million - $13.3 Million	-85,000 Reduced 56.67%	65,000 $9.61 Million
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $4.85 Million - $7.26 Million	-50,000 Reduced 25.0%	150,000 $16.9 Million
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $4.57 Million - $6.96 Million	50,000 Added 33.33%	200,000 $27.8 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $7.19 Million - $8.92 Million	-75,000 Reduced 33.33%	150,000 $14.4 Million
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $17.1 Million - $21.1 Million	-160,000 Reduced 41.56%	225,000 $25.9 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $16.2 Million - $33.8 Million	260,000 Added 208.0%	385,000 $45.3 Million
Q4 2018 Feb 14, 2019	SELL	$55.16 - $69.67 $5.52 Million - $6.97 Million	-100,000 Reduced 44.44%	125,000 $7.83 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $3.19 Million - $3.81 Million	50,000 Added 28.57%	225,000 $15.9 Million
Q2 2018 Aug 14, 2018	BUY	$58.55 - $73.92 $2.05 Million - $2.59 Million	35,000 Added 25.0%	175,000 $11.6 Million
Q1 2018 May 15, 2018	SELL	$38.98 - $68.04 $4.29 Million - $7.48 Million	-110,000 Reduced 44.0%	140,000 $9.16 Million
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $1.6 Million - $2.02 Million	50,000 Added 25.0%	250,000 $10 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $5.38 Million - $7.42 Million	200,000	200,000 $7.25 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ghost Tree Capital, LLC with notifications on news.

Account

Ghost Tree Capital, LLC Ascendis Pharma A/S Transaction History